Results 131 to 140 of about 13,105 (295)

Sanção administrativa e termo de compromisso como instrumentos de enforcement à disposição da CVM: uma análise à luz de seus efeitos

open access: yesRevista de Direito Setorial e Regulatório
[Purpose] To identify the incentives that administrative sanctions and settlement agreements in sanctioning processes can create for aligning the behavior of regulated agents with the regulations governing the securities market.
Carolina Estarque
doaj  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

European Court of Human Rights case law on administrative sanctions [PDF]

open access: yes, 2013
An analysis of the impact of art.
F. Goisis
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

The prescribed administrative sanctions on the protection of competition law

open access: yes, 2008
Çalışmamızın konusu Rekabetin Korunması Hakkında Kanunda Öngörülen İdari para yaptırımlarıdır. Rekabet alanı sosyal hayatın hassas alanlarından birisidir ve bu özelliği nedeniyle idari yaptırımlar ile korunmaktadır.
Koç, Emin
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

The system in law of administrative sanctions

open access: yes, 2007
Administrative sanctions are sanctions of the administration which is applied by an act on the explicit power derived from law. It is possible to apply an administrative sanction without a verdict.
Karabulut, Mustafa
core  

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

Ejecutividad y prescripción de las sanciones administrativas en las Leyes 39/2015, del Procedimiento Administrativo Común de las Administraciones Públicas y 40/2015, de Régimen Jurídico del Sector Público

open access: yesRevista Vasca de Administración Pública, 2018
The Act 40/2015 of the legal regime of the Public Sector has introduced a new rule on the calculation of the limitation period to be applied to sanctions in cases where hierarchichal appeal filed against them had been rejected by administrative silence ...
Carmen Chinchilla Marín
doaj   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy